MOREPEN

MOREPEN 40 Years of Excellence

Date: 06/08/2026

To,

National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai- 400 051
Symbol: MOREPENLAB

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400 001
Scrip Code: 500288

Subject: Intimation *w.r.t.*, allotment of equity shares by Morepen RX Limited, wholly owned subsidiary, to the company

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

Dear Sir/ Madam,

Pursuant to Regulation 30 of the SEBI Listing Regulations, we wish to inform you that Morepen RX Limited ('MRX'), a wholly owned subsidiary of the company, has informed that its Board of Director of MRX at their meeting held today *i.e.*, 6th August 2026, has allotted 2,00,00,000 (Two Crore) equity shares of Rs. 10/- (Rupees Ten Only) each, at par, aggregating to Rs. 20,00,00,000/- (Rupees Twenty Crores Only), to the company pursuant to its rights issue.

Further, the Finance Committee of the Board of Directors of the company, at its meeting held today, has, *inter alia*, taken note aforesaid allotment.

Consequent to aforesaid allotment, the company's shareholding in MRX has increased to 2,70,82,356 (Two Crore Seventy Lakh Eighty-Two Thousand Three Hundred Fifty-Six) equity shares. The MRX continues to remain a wholly owned subsidiary of the company.

The details as required under the SEBI Listing Regulations read with SEBI master Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January 2026, is given in the **Annexure.**

Please take note of the above.

Thanking you,

Yours faithfully,

For Morepen Laboratories Limited

Vipul Kumar Srivastava

Digitally signed by Vipul Kumar Srivastava
DN: c=IN, o=Personal, title=5965,
pseudonym=27r5blzck0qifj1phgwaves8do39myx6,
2.5.4.20=824342118b98561bde2c7d0b1ad7b62196947c41b456377b3cbe9a983c527111, postalCode=110078, st=Delhi,
serialNumber=1363f5e45381fa8dd66dee65e3bc15c08e5b41badb071c1b5de04ef8874db223, cn=Vipul Kumar Srivastava
Date: 2026.08.06 16:52:36 +05'30'

Vipul Kumar Srivastava
Company Secretary
F-12148

Encl.: a/a.

MOREPEN

Annexure

Disclosure in terms of Regulation 30 read with SEBI master Circular No. HO/49/14/14(7)2025-CFD POD2/I/3762/2026 dated 30th January 2026

Sr. no.	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc.	Morepen RX Limited (MRX), a wholly owned subsidiary of the company; MRX had a turnover of Rs. 5,449.84 Lakh and a net worth of Rs. 47.72 Lakh based on the audited financial statements for the financial year ended 31st March 2026.
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	Yes, MRX is a wholly owned subsidiary and a related party of the company. Mr. Sanjay Suri, Mr. Varun Suri and Ms. Shalu Suri members of promoter group of the company are also the Directors of MRX. Except as stated above, none of the promoter(s), promoter group or group companies has any other interest in MRX.
3.	Industry to which the entity being acquired belongs	Pharmaceutical
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Subscription to the rights issue of MRX to strengthen its capital base and support its business operations.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	Not applicable
6.	Indicative time period for completion of the acquisition	Not applicable
7.	Consideration - whether cash consideration or share swap or any other form and details of the same.	Cash
8.	Cost of acquisition and/or the price at which the shares are acquired	2,00,00,000 (Two Crore) equity shares of Rs. 10/- each, at par, to cost is Rs. 20,00,00,000/- (Rupees Twenty Crores Only).

<table>
<tr><td>9.</td><td>Percentage of shareholding / control acquired and / or number of shares acquired</td><td>2,00,00,000 (Two Crore) equity shares of Rs. 10/- each, at par, in the rights issue of MRX.

The company continues to hold 100% of the equity share capital of MRX.</td></tr>
<tr><td>10.</td><td>Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years' turnover, country in which the acquired entity has presence and any other significant information (in brief)</td><td>MRX was incorporated on 17th March 2023, and is engaged the business of sales and marketing of Branded Prescription ("Rx") products. It primarily operates in India. The history of turnover is as under:

<table><tr><th>Financial Year</th><th>Turnover (Rs. in/lakh)</th></tr><tr><td>2025-26</td><td>5,449.84</td></tr><tr><td>2024-25</td><td>11,276.35</td></tr><tr><td>2023-24</td><td>8,383.45</td></tr></table></td></tr>
</table>